STOCK TITAN

Nyxoah SA Ordinary Shares - NYXH STOCK NEWS

Welcome to our dedicated page for Nyxoah SA Ordinary Shares news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on Nyxoah SA Ordinary Shares stock.

Nyxoah SA Ordinary Shares (symbol: NYXH) is at the forefront of medical technology, focusing on innovative solutions to address Obstructive Sleep Apnea (OSA). The company is committed to enhancing the lives of individuals suffering from sleep-disordered breathing conditions through its state-of-the-art products and services.

Nyxoah's flagship product, the Genio system, is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe OSA. This user-centered system provides an effective and non-invasive treatment option for a condition that has been linked to increased mortality risks and various comorbidities, including cardiovascular diseases, depression, and stroke.

The Genio system stands out in the market due to its unique approach, focusing on bilateral stimulation to open the airway during sleep, thereby improving the quality of life for patients. The development and commercialization of this innovative platform underscore Nyxoah's commitment to addressing critical health issues with cutting-edge technology.

Recent achievements of Nyxoah include advancements in clinical trials, expansion into new markets, and strategic partnerships that underscore the company's growth potential and dedication to innovation. Financially, Nyxoah has shown resilience and strategic foresight, ensuring robust investment in research and development to maintain its competitive edge.

Nyxoah continually updates its stakeholders with the latest company news, ensuring transparency and fostering investor confidence. With its headquarters in Belgium, Nyxoah is well-positioned to expand its global presence and continue its mission of providing effective solutions for OSA and related conditions.

Stay informed with the latest updates and developments from Nyxoah to keep track of their performance, events, and strategic initiatives.

Rhea-AI Summary

Nyxoah announced the resignation of Raymond Cohen from its board of directors, effective October 18, 2022. This change occurs in a company focused on innovative solutions for treating Obstructive Sleep Apnea (OSA), highlighting the need for strong leadership amid ongoing product developments. The company’s Genio® system received CE Mark approval in 2019 and is currently undergoing the DREAM IDE pivotal study for FDA approval. This management shift may impact Nyxoah’s strategic direction as it continues to expand its market presence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
management
-
Rhea-AI Summary

Nyxoah will participate in the Jefferies London Healthcare Conference from November 15-17, 2022. The event will be held at The Waldorf Hilton, London. CEO Olivier Taelman will provide a corporate update during a fireside chat on November 17 at 10:25am GMT. A webcast will be available on the Company's Investor Relations page. Nyxoah specializes in treating Obstructive Sleep Apnea with its lead product, the Genio® system, which received European CE Mark approval in 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.65%
Tags
conferences
-
Rhea-AI Summary

Nyxoah has announced the release date for its third quarter financial results, scheduled for November 8, 2022, after market close. The medical technology company specializes in innovative solutions for Obstructive Sleep Apnea (OSA). The company’s management will host a conference call at 10:30 PM CET / 4:30 PM ET to discuss the results. Interested investors can register for the call online. Nyxoah is known for its Genio® system, which has received CE mark approval for treating OSA and is currently conducting studies for FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
Rhea-AI Summary

Nyxoah SA disclosed new share capital information in a regulatory announcement dated September 30, 2022. The company reported a total share capital of EUR 4,440,069.16 and indicated that there are 25,846,279 securities carrying voting rights, consisting entirely of ordinary shares. Furthermore, it outlined the number of subscription rights for various Employee Stock Option Plans (ESOP) dating from 2016 to 2021, which entitle holders to subscribe for a total of 1,916,625 additional securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
none
-
Rhea-AI Summary

Nyxoah, a medical technology company specializing in solutions for Obstructive Sleep Apnea (OSA), will participate in the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022, in Everett, MA. Management will conduct one-on-one meetings with investors on September 9. The announcement comes as Nyxoah continues to advance its Genio® system, a revolutionary treatment for OSA. With CE Mark approval since 2019 and ongoing studies for FDA approval, Nyxoah aims to improve patient outcomes and expand its market presence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
-
Rhea-AI Summary

Nyxoah reported strong financial results for Q2 and H1 2022, highlighted by revenues of €935,000, a 5x increase from the previous year. The company completed enrollment in the DREAM U.S. pivotal trial and plans to release 12-month clinical data in fall 2023. Furthermore, FDA approved the ACCCESS study and the Genio® 2.1 system. However, Nyxoah experienced an operating loss of €7.4 million in Q2, with R&D and SG&A expenses rising significantly. The cash position stood at €123.3 million, offering sufficient liquidity for upcoming U.S. commercialization efforts in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
Rhea-AI Summary

Nyxoah has announced a distribution agreement with Acurable to offer the AcuPebble SA100 home sleep test for Obstructive Sleep Apnea patients in Germany. This advanced wearable device captures acoustic signals for rapid diagnosis, demonstrating high sensitivity and specificity. The AcuPebble is CE marked and FDA cleared. Nyxoah aims to enhance patient access to effective OSA diagnosis and treatment. The launch is expected in Q4 2022, aligning with Nyxoah's mission to improve the quality of life for OSA patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
Rhea-AI Summary

Nyxoah, a medical technology company based in Belgium, has announced its participation in the Canaccord Genuity 42nd Annual Growth Conference in Boston from August 8 to 11, 2022. Olivier Taelman, CEO, will present a corporate update on August 10 at 3:30pm EDT. Investors can access the live webcast on the Company's Investor Relations website. Nyxoah specializes in solutions for Obstructive Sleep Apnea (OSA) and features the Genio® system, an innovative therapy recognized with a CE Mark since 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Nyxoah SA announced the release of its Q2 and H1 2022 financial results on August 8, 2022, after market close. The healthcare company specializes in solutions for Obstructive Sleep Apnea (OSA), with its lead product, the Genio® system, already CE marked. Following positive study outcomes, Nyxoah expanded its therapeutic indications, enhancing its market position. Investors can join a conference call on the same day at 10:30pm CET / 4:30pm ET to discuss the results. For further details, visit the investor relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
Rhea-AI Summary

Nyxoah has announced the CE Mark Approval for its next-generation Genio® 2.1 system, enhancing the treatment of Obstructive Sleep Apnea (OSA)

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.22%
Tags
none

FAQ

What is the current stock price of Nyxoah SA Ordinary Shares (NYXH)?

The current stock price of Nyxoah SA Ordinary Shares (NYXH) is $8.01 as of December 20, 2024.

What is the market cap of Nyxoah SA Ordinary Shares (NYXH)?

The market cap of Nyxoah SA Ordinary Shares (NYXH) is approximately 298.7M.

What is Nyxoah SA's core business?

Nyxoah SA focuses on developing and commercializing innovative solutions to treat Obstructive Sleep Apnea (OSA).

What is the Genio system?

The Genio system is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe Obstructive Sleep Apnea (OSA).

What conditions does Nyxoah's Genio system address?

The Genio system targets Obstructive Sleep Apnea (OSA), which is associated with increased mortality risk and comorbidities like cardiovascular diseases, depression, and stroke.

How does Nyxoah update its stakeholders?

Nyxoah ensures transparency by continually updating stakeholders with the latest company news, performance information, and strategic initiatives.

Where is Nyxoah SA headquartered?

Nyxoah SA is headquartered in Belgium, with its innovative solutions reaching markets worldwide.

What makes the Genio system unique?

The Genio system is unique due to its bilateral stimulation approach, providing an effective and non-invasive treatment for OSA by opening the airway during sleep.

What recent achievements has Nyxoah accomplished?

Nyxoah has made significant strides in clinical trials, market expansion, and strategic partnerships, highlighting its growth potential and commitment to innovation.

What is OSA?

Obstructive Sleep Apnea (OSA) is a sleep disorder characterized by repeated episodes of partial or complete obstruction of the upper airway during sleep, leading to breathing interruptions.

Why invest in Nyxoah SA?

Nyxoah SA offers innovative solutions for OSA, a condition with significant health risks. The company's continuous advancements, strategic partnerships, and commitment to innovation make it a promising investment opportunity.

What are Nyxoah's future plans?

Nyxoah aims to expand its global presence, enhance its product offerings, and continue investing in research and development to bring effective solutions for sleep-disordered breathing conditions.

Nyxoah SA Ordinary Shares

Nasdaq:NYXH

NYXH Rankings

NYXH Stock Data

298.67M
22.46M
41.74%
35.37%
0.12%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Mont-Saint-Guibert